Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B

Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B

Nucleos(t)ide analogues are first-line therapies for the treatment of chronic hepatitis B. However, the efficacy and safety of long-term treatment and the necessary duration of therapy remains the subject of discussion. Aim. To assess the efficacy and safety of long-term treatment with nucleos(t)ide...

Full description

Bibliographic Details
Main Authors:	E K Ibragimov, D T Abdurakhmanov, T P Rozina, E N Nikulkina, E L Tanaschuk, A V Odintsov, S V Panevkina, S V Moiseev
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2019-02-01
Series:	Терапевтический архив
Subjects:	chronic hepatitis b nucleos(t)ide analogues virologic response hbeag seroconversion hbsag clearance alt normalization safety
Online Access:	https://ter-arkhiv.ru/0040-3660/article/viewFile/32918/pdf

Similar Items

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice
by: Mingfan Geng, et al.
Published: (2017-09-01)

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
by: Margarita Papatheodoridi, et al.
Published: (2020-02-01)

Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon
by: Peipei Wang, et al.
Published: (2023-01-01)

Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy
by: Bei Jiang, et al.
Published: (2022-12-01)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
by: Sang Kyung Jung, et al.
Published: (2015-03-01)

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01)

Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
by: Yi-Cheng Chen, et al.
Published: (2020-05-01)

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
by: Nae-Yun Heo
Published: (2017-06-01)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)

Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection
by: Fangfang Sun, et al.
Published: (2022-11-01)

Trend patterns of HBsAg kinetics in chronic hepatitis B patients during nucleos(t)ide analogue therapy based on ARMA models
by: Hsien-Chung Yu, et al.
Published: (2023-06-01)

A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues
by: Yan Gu, et al.
Published: (2024-01-01)

The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
by: Jae Min Park, et al.
Published: (2021-09-01)

Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy
by: Chi-Jung Wu, et al.
Published: (2021-08-01)

Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients
by: Zhang C, et al.
Published: (2016-03-01)

Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients
by: Jing Zhao, et al.
Published: (2023-03-01)

HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining
by: Xizhan Xu, et al.
Published: (2017-07-01)

Dynamics of Serum Pregenome RNA in Chronic Hepatitis B Patients Receiving 96-Month Nucleos(t)ide Analog Therapy
by: Yachao Tao, et al.
Published: (2022-02-01)

Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients
by: Jong Hwa Na, et al.
Published: (2021-06-01)

Current Trend in Antiviral Therapy for Chronic Hepatitis B
by: Rong-Nan Chien, et al.
Published: (2022-02-01)

Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study
by: Li Y, et al.
Published: (2021-08-01)

Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
by: Li Liu
Published: (2020-02-01)

Lamivudine: fading into the mists of time
by: Jonggi Choi, et al.
Published: (2017-12-01)

Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B
by: Linqing Xie, et al.
Published: (2019-07-01)

Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B
by: Jie Peng, et al.
Published: (2015-01-01)

The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment
by: Lina Wu, et al.
Published: (2021-02-01)

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
by: Wei Y, et al.
Published: (2019-09-01)

Circulating miR-122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide Analogs
by: Yin Wu, et al.
Published: (2019-03-01)

Hepatitis B virus associated cirrhosis: overview of prognostic and management
by: Marilena Stoian
Published: (2023-06-01)

Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment
by: Lisa Sandmann, et al.
Published: (2024-02-01)

Serological detection of hepatitis B virus e antigen and TNF-α in a dialysis patient
by: Aneeda Khraibet Abed, et al.
Published: (2023-01-01)

Detection of Mediterranean Hepatitis B in a 45 Years Old Man in Mahdieh Clinical Laboratory, Isfahan, Iran
by: Majid Komijani, et al.
Published: (2017-09-01)

High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study
by: Prince Kofi Parbie, et al.
Published: (2022-08-01)

Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients
by: Wei Teng, et al.
Published: (2021-04-01)

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil
by: Camila V Pereira, et al.
Published: (2016-04-01)

NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B
by: E. A. Elpaeva, et al.
Published: (2015-12-01)

Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy
by: Er-Mei Li, et al.
Published: (2021-08-01)

48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients
by: Li Gao, et al.
Published: (2020-05-01)

The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights
by: Fabrizio Fabrizi, et al.
Published: (2023-02-01)

Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review
by: Faydra I. Lieveld, et al.
Published: (2013-05-01)